淫羊藿有效成分治疗乳腺癌作用机制的研究进展

Research progress on mechanisms of active constituents of Epimedii Folium in treatment of breast cancer

乳腺癌是女性最常见的恶性肿瘤,在我国与发达国家的5年生存率相较仍有差距。淫羊藿作为补肾中药具有悠久的用药历史,现代研究表明淫羊藿及其有效成分(淫羊藿素、淫羊藿苷、淫羊藿次苷Ⅱ等)具有多途径、多靶点的抗肿瘤特性,是具有研究价值的治疗乳腺癌药物。对淫羊藿及其有效成分抗乳腺癌作用的分子机制进行梳理,从抑制乳腺癌细胞增殖、促进乳腺癌细胞凋亡、抑制乳腺癌侵袭转移、改善乳腺癌免疫微环境、减少耐药抵抗并协同增效以及抑制乳腺癌干细胞增殖等机制角度对淫羊藿的抗乳腺癌作用进行阐述,为淫羊藿有效成分与化学药协同抗乳腺癌交叉机制的深入研究与临床药物制剂的开发应用提供依据。

Breast cancer is the most common malignant tumor in women,and there is still a gap between the 5-year survival rate in China and that in developed countries. Yinyanghuo(Epimedii Folium) is a traditional Chinese medicine with long history for its effects of kidneytonifying. Researches have shown that Epimedii Folium and its active constituents(icaritin,icariin and icariside Ⅱ) have synergistic anti-tumor effect of multiple pathways and multiple targets which means it has research value for breast cancer treatment. The molecular mechanisms of the anti-breast cancer effects of Epimedii Folium and its active ingredients have been investigated,and the anti-breast cancer effects of Epimedii Folium have been described from the perspectives of inhibiting breast cancer cell proliferation,including inhibiting breast cancer cells proliferation,promoting breast cancer cells apoptosis,inhibiting breast cancer invasion and migration,improving breast cancer immune microenvironment,reducing drug resistance,synergizing with occidental medicine and inhibiting breast cancer stem cells proliferation were reviewed in this paper,which will provide basis for further research on cross-mechanisms of synergy action between Epimedii Folium and western medicine in treatment of breast cancer and development and application of clinical pharmaceutical preparations.